Published in Immunotherapy Weekly, August 9th, 2006
MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or are intolerant to current treatment options including one or more tumor necrosis factor (TNF) inhibitors. MabThera is the first selective B cell therapy for RA with a fundamentally different treatment approach.
B cells play a key role in driving the RA disease process and MabThera is thought to break this process so preventing disease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.